Skip to main content

Pralatrexate, a new hope for aggressive T-cell lymphomas?

Clinical and Translational Oncology volume 11, pages 215–220 (2009)Cite this article

Abstract

Aggressive T-cell lymphomas represent a particularly poor-prognosis subgroup of lymphomas. This is especially true for patients with recurrent or refractory disease who typically have a limited response to salvage therapy and an extremely poor overall survival. There is thus a strong need to develop potentially active drugs for these malignancies. Pralatrexate is a novel antifolate designed to have high affinity for the reduced folate carrier type 1. Preclinical and clinical studies have demonstrated that pralatrexate has significant activity against T-cell lymphomas. The dose-limiting toxicity for pralatrexate is mucositis, which could be abrogated with folic acid and vitamin B12 supplementation. Pralatrexate is now being evaluated in phase II clinical trials for the treatment of peripheral T-cell lymphoma, and in a phase I/II trial in combination with gemcitabine for the treatment of non-Hodgkin’s lymphoma. Because of the limited therapies available for aggressive T-cell lymphoma, pralatrexate could secure a niche for the treatment of this condition, provided ongoing clinical trials and future phase III trials confirm the efficacy of the drug.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Harris NL, Jaffe ES, Stein H et al (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84:1361–1392

    PubMed  CAS  Google Scholar 

  2. Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon

    Google Scholar 

  3. The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood 89:3909–3918

    Google Scholar 

  4. Anderson JR, Armitage JO, Weisenburger DD et al (1998) Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Ann Oncol 9:717–720

    PubMed  Article  CAS  Google Scholar 

  5. International T-Cell Lymphoma Project (2008) International peripheral T-cell and natural killer/Tcell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol 26:4124–4130

    Article  Google Scholar 

  6. Coiffier B, Brousse N, Peuchmaur M et al (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomaes Aggressives). Ann Oncol 1:45–50

    PubMed  CAS  Google Scholar 

  7. Evens AM, Gartenshaus RB (2004) Treatment of T-cell Non-Hodgkin’s lymphoma. Curr Treat Opt Oncol 5:289–303

    Article  Google Scholar 

  8. Lopez-Guillermo A, Cid J, Salar A et al (1998) Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. Ann Oncol 9:849–855

    PubMed  Article  CAS  Google Scholar 

  9. Rudiger T, Weisenburger DD, Anderson JR et al (2002) Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol 13:140–149

    PubMed  Article  CAS  Google Scholar 

  10. Campo E, Gaulard P, Zucca E et al (1998) Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. Ann Oncol 9:835–843

    PubMed  Article  CAS  Google Scholar 

  11. Molina JR (2008) Pralatrexate, a dihydrofolate reductase inhibitor for the potential treatment of several malignancies. IDrugs 11:508–521

    PubMed  CAS  Google Scholar 

  12. Gangjee A, Jain HD, Kurup S (2008) Recent advances in classical and non-classical antifolates as antitumor and antiopportunistic infection agents: Part II. Anticancer Agents Med Chem 8:205–231

    PubMed  Article  CAS  Google Scholar 

  13. Assaraf YG (2007) Molecular basis of antifolate resistance. Cancer Metastasis Rev 26:153–181

    PubMed  Article  CAS  Google Scholar 

  14. Dhaliwal HS, Rohatiner AZ, Gregory W et al (1993) Combination chemotherapy for intermediate and high-grade non-Hodgkin’s lymphoma. Br J Cancer 68:767–774

    PubMed  CAS  Google Scholar 

  15. Patte C (2002) Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Hematol 15:695–711

    Article  CAS  Google Scholar 

  16. Fotoohi AK, Albertioni F (2008) Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells. Leuk Lymphoma 49:410–426

    PubMed  Article  CAS  Google Scholar 

  17. Sirotnak FM, DeGraw JI, Moccio DM et al (1984) New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties. Cancer Chemother Pharmacol 12:18–25

    PubMed  CAS  Google Scholar 

  18. Gralla RJ (1995) Edatrexate studies in non-small cell lung cancer. Lung Cancer 12[Suppl 1]:S187–191

    PubMed  Article  Google Scholar 

  19. DeGraw JI, Colwell WT, Piper JR et al (1993) Synthesis and antitumor activity of 10-propargyl-10-deazaaminopterin. J Med Chem 36:2228–2231

    PubMed  Article  CAS  Google Scholar 

  20. Sirotnak FM, DeGraw JI, Colwell WT et al (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313–318

    PubMed  Article  CAS  Google Scholar 

  21. Wang ES, O’Connor O, She Y et al (2003) Activity of a novel antifolate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression. Leuk Lymphoma 44:1027–1035

    PubMed  Article  CAS  Google Scholar 

  22. O’Connor OA (2006) Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 18:591–597

    PubMed  Article  CAS  Google Scholar 

  23. Toner LE, Vrhovac R, Smith EA et al (2006) The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin’s lymphoma. Clin Cancer Res 12:924–932

    PubMed  Article  CAS  Google Scholar 

  24. Cadman E, Eiferman F (1979) Mechanism of synergistic cell killing when methotrexate precedes cytosine arabinoside: study of L1210 and human leukemic cells. J Clin Invest 64:788–797

    PubMed  Article  CAS  Google Scholar 

  25. Krug LM, Ng KK, Kris MG et al (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6:3493–3498

    PubMed  CAS  Google Scholar 

  26. Mould DR, Sweeney K, Duffull S et al (2007) A population pharmacokinetic and pharmacodynamic evaluation of pralatrexate in patients with hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 110:1370

    Google Scholar 

  27. O’Connor O, Hamlin P, Neylon E et al (2006) Early-phase experience with pralatrexate (10-propargyl-10-deazaaminopterin [PRX]), a novel antifolate with high affinity for the reduced folate carrier, in patients with chemotherapy refractory lymphoproliferative malignancies. Eur J Cancer 4[Suppl 12]:abstract 461

    Google Scholar 

  28. O’Connor, Hamlin PA, Portlock C et al (2007) Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma. Br J Haematol 139:425–428

    PubMed  Article  CAS  Google Scholar 

  29. Leitenberger JJ, Berthelot CN, Polder KD et al (2008) CD4+ CD56+ hematodermic/plasmacytoid dendritic cell tumor with response to pralatrexate. J Am Acad Dermatol 58:480–484

    PubMed  Article  Google Scholar 

  30. O’Connor OA, Pro B, Pinter-Brown L et al (2008) PROPEL: a multi-center phase 2 open-label study of pralatrexate (PDX) with vitamin B12 and folic acid supplementation in patients with relapsed or refractory peripheral T-cell lymphoma. Blood (ASH Annual Meeting Abstracts 2008) 112:Abstract 261

  31. Horwitz SM, Vose JM, Advani R et al (2008) A phase 1/2A open-label study of pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies. Blood (ASH Annual Meeting Abstracts 2008) 112:Abstract 1570

Download references

Author information

Affiliations

  1. Servicio de Oncohematología, Hospital Costa del Sol, Autovía A-7, Km 187, ES-29600, Marbella, Málaga, Spain

    Antonio Rueda, María Casanova & Ángeles Medina-Pérez

  2. Servicio de Oncología Médica, Hospital Clínico Universitario, Málaga, Spain

    Cristina Quero

Authors
  1. Antonio Rueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. María Casanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cristina Quero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ángeles Medina-Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio Rueda.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rueda, A., Casanova, M., Quero, C. et al. Pralatrexate, a new hope for aggressive T-cell lymphomas?. Clin Transl Oncol 11, 215–220 (2009). https://doi.org/10.1007/s12094-009-0343-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-009-0343-9

Key words

  • Aggressive T-cell lymphomas
  • Pralatrexate